Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Moscow region, prosp. Akad. Semenova, 1, 142432 Chernogolovka, Russian Federation.
Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Moscow region, prosp. Akad. Semenova, 1, 142432 Chernogolovka, Russian Federation.
J Inorg Biochem. 2025 Jan;262:112747. doi: 10.1016/j.jinorgbio.2024.112747. Epub 2024 Sep 29.
A new promising binuclear tetranitrosyl iron complex with 2-methoxythiophenolyl of the composition [Fe(CHOS)(NO)] (complex 1), which acts on the therapeutic targets of cardiovascular diseases, guanylate and adenylate cyclase, has been synthesized. X-ray diffraction data show the presence of two isoforms of complex 1; according to quantum chemical calculations, the structure of only the trans isomer is stable in solutions. The processes of transformation of complex 1 in DMSO, in aqueous solutions, as well as in the presence of bovine serum albumin, reduced glutathione, and mucin were studied. DMSO promotes the decomposition of the original complex 1 into mononuclear products. In biological systems, the mechanisms of decomposition of the complex 1 differ from aqueous solutions. In albumin solution, a gradual formation of a high-molecular-weight dinitrosyl complex is observed, obtained by coordinating the [Fe(NO)] fragment with the amino acid groups of the protein. In the presence of mucin, an EPR signal from stable mononitrosyl products is observed. The introduction of glutathione into the system of the complex 1 leads to the replacement of one initial thioligand with glutathione. In the model systems under study, a more efficient and prolonged generation of NO groups is observed compared to a buffer solution. The obtained data on the influence of the environment on the properties of the complex 1 in combination with a study of their effect on enzymes allow us to recommend it for further study as a potential drug with vasodilator, antianginal, and hypotensive properties.
一种新的有前景的双核四硝基金属铁配合物,其组成为[Fe(CHOS)(NO)](配合物 1),它作用于心血管疾病的治疗靶点,如鸟苷酸环化酶和腺苷酸环化酶,已被合成。X 射线衍射数据显示配合物 1 存在两种异构体;根据量子化学计算,只有反式异构体在溶液中的结构是稳定的。研究了配合物 1 在 DMSO 中的转化过程、在水溶液中的转化过程以及在牛血清白蛋白、还原型谷胱甘肽和粘蛋白存在下的转化过程。DMSO 促进原始配合物 1 分解为单核产物。在生物系统中,配合物 1 的分解机制与水溶液不同。在白蛋白溶液中,观察到逐渐形成一种高分子量的双硝基金属配合物,该配合物通过与蛋白质的氨基酸基团配位来获得[Fe(NO)]片段。在粘蛋白存在下,观察到稳定的单硝基金属产物的 EPR 信号。向配合物 1 体系中引入谷胱甘肽会导致一个初始硫醇配体被谷胱甘肽取代。与缓冲溶液相比,在所研究的模型体系中观察到 NO 基团更有效和持久的生成。与研究它们对酶的影响相结合,关于环境对配合物 1 性质的影响的这些数据使我们推荐其作为一种具有血管扩张、抗心绞痛和降压特性的潜在药物进一步研究。